Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
Ut Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
UCART-22 |
UCART-22 |
Phase 1 Clinical |
Cellectis |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CAR-20-19-22(Medical College of Wisconsin) |
CAR-20-19-22 |
|
The Medical College Of Wisconsin Nonprofit |
|
Details
|
RD-102 |
RD-102 |
Phase 1 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse |
Details
|
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD22 CAR-T Cell Therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Solid tumours; Sarcoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms |
Details
|
GC-022 |
GC-022; GC-022F |
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Leukemia, Lymphoid |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University |
Lymphoma, B-Cell |
Details
|
Anti-CD22 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase 2 Clinical |
Aikangd Biomedical Technology (Suzhou) Co Ltd |
Lymphoma, B-Cell |
Details
|
Anti-CD22 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 1 Clinical |
Wuhan Bio-Raid Biotechnology |
Lymphoma, B-Cell; Multiple Myeloma |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Leukemia; Lymphoma, B-Cell |
Details
|
Anti-CD22-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 2 Clinical |
Kecellitics Biotech Company Ltd |
Leukemia; Lymphoma |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology |
Leukemia, Lymphoid |
Details
|
Anti-CD22 CAR T cell therapy (Shanghai GeneChem) |
|
Phase 1 Clinical |
Shanghai Genechem Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CART22-cells |
CART22-cells |
Phase 1 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Leukemia; Lymphoma, B-Cell |
Details
|
CD22-targeted CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Neoplasms, Plasma Cell |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) |
|
Phase 1 Clinical |
University Of Colorado, Denver, Usa |
Lymphoma, Non-Hodgkin |
Details
|
Anti CD22 chimeric antigen receptor T cell therapy (Shanghai Yake Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd, Beijing Boren Hospital, The First Affiliated Hospital Of Zhejiang University School Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
|
Phase 1 Clinical |
China Immunotech Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
TRPH-222 |
CD22-4AP; TRPH-222; CAT-02-106 |
Phase 1 Clinical |
Catalent Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-T |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Neoplasms |
Details
|
CD19/CD22 bispecific CAR-T (Zhejiang University) |
|
Phase 2 Clinical |
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) |
LCAR-L10D |
Phase 1 Clinical |
Nanjing Legend Biotechnology Co Ltd, Second Affiliated Hospital Xi'An Jiaotong University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
JCAR-018 |
JCAR-018 |
Phase 1 Clinical |
National Cancer Institute, Opus Bio |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Epratuzumab |
AMG-412; CDP-3194; IMMU-103; IMMU-1903; IMMU-hLL2 |
Phase 3 Clinical |
Immunomedics Inc |
Lymphoma, B-Cell; Sjogren's Syndrome; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD22-CART |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) |
CT-120 |
Phase 2 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
Epratuzumab-cys-tesirine |
ADCT-602 |
Phase 2 Clinical |
Adc Therapeutics |
Leukemia, Lymphoid |
Details
|
GTB-1550 |
DT-2219; OXS-1550; DT-2219ARL; IND-100780 |
Phase 2 Clinical |
University Of Minnesota |
Leukemia; Lymphoma, B-Cell |
Details
|
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
|
Phase 1 Clinical |
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Hematologic Neoplasms |
Details
|
Anti-CD22 CAR-T cell therapy (No. 307 Hospital) |
|
Phase 2 Clinical |
The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
AUTO-3 |
AUTO-3 |
Phase 2 Clinical |
University College London |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
ThisCAR-T-22(Fundamenta Therapeutics) |
ThisCAR-T-22 |
Phase 1 Clinical |
|
Lymphoma, B-Cell |
Details
|
Bispecific CD19/22 CAR T cells |
|
|
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
|
Details
|
anti-CD22-CAR-transduced T cells(Southwest Hospital) |
|
Phase 2 Clinical |
Southwest Hospital |
Leukemia; Lymphoma |
Details
|
4SCAR19/22 |
4SCAR19/22 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CD19/CD22 targeted CAR-T cells |
|
Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CTA-101 |
CTA-101 |
Phase 1 Clinical |
Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
IMJ-995 |
IMJ-995 |
Phase 1 Clinical |
Novartis Pharma Ag |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Suciraslimab |
SM-06; SM-03 |
Phase 3 Clinical |
Lonn Ryonn Pharma Ltd, Sinomab Bioscience Ltd |
Arthritis, Rheumatoid; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin |
Details
|
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|